Final California Marijuana Industry Rules May Not Be Made Public Until January

Although California’s final cannabis industry regulations will reportedly be completed Monday, many industry insiders likely won’t be able to read them until January.

That may be a disappointment to marijuana businesses that were anticipating being able to see the final rules sooner than later.

“We expect to send our final version of permanent regulations to the Office of Administrative Law (OAL) on Monday, Dec. 3,” Alex Traverso, spokesman for the California Bureau of Cannabis Control (BCC), wrote in an email to Marijuana Business Daily.

“That will kick off a 30-day review period for OAL. The regulations will not be made public while OAL conducts its review,” he added.

Traverso wrote that the anticipated public release of final regulations after the OAL has given approval is “likely in early- (or) mid-January.”

He noted the BCC is exploring possible ways to make the regulations public sooner.

The state’s Department of Food and Agriculture, which oversees cultivators, and the Department of Public Health, which governs MJ manufacturers, will also be sending final rules to the OAL on Monday.

A similar timeline is expected for the regulations to be made public from all three agencies.

The regulations have taken more than a year for state officials to craft, and they have gone through multiple revisions throughout 2018.

The latest drafts of permanent rules were released Oct. 19.

Traverso said that until the OAL approves the final rules, the industry will be governed by emergency regulations that were re-adopted in June.

The OAL did not immediately respond to a MJBizDaily‘s request for comment as to when the final regulations might be published online.

John Schroyer can be reached at [email protected]

Original Article Source: https://mjbizdaily.com/final-california-marijuana-industry-rules-may-not-be-made-public-until-january/

Comments

Could CBD Lead To The Development Of Safer Antipsychotic Medications?

Antipsychotic medications are important for managing a number of different psychiatric ailments, including bipolar disorders, schizophrenia, and even dementia. These drugs can greatly improve the manageability of symptoms that often distort one’s experience of reality. They can also create major mood disruptions and lead to a number of behavioral and emotional difficulties. Antipsychotic and anti-psychosis medications can be life-changing for people with such disorders, enabling them to live more normal and manageable lives without their symptoms taking over. These drugs work by regulating neurotransmitters in the brain so that naturally occurring imbalances and dysfunctions no longer disrupt mental and emotional processes. Often, reaching this outcome is much easier said than done; it can take a lot of time to find courses and combinations of treatments that work. It’s sometimes necessary to make adjustments to find the right balance for the individual and it’s not unusual for outc...

A Dozen US Governors Ask Congressional Leaders To Back Federal Marijuana Reform

A bipartisan coalition of 12 governors from states that have legalized medical or recreational cannabis sent a letter to congressional leaders, asking for their support in getting a major marijuana reform bill through the U.S. House and Senate. The governors of California, Colorado, Maryland, Massachusetts, Nevada, New York, North Dakota, Oregon, Pennsylvania, Utah, Vermont and Washington state are backing the STATES Act – which would codify in federal law that marijuana regulations are to be left to the states instead of the federal government – while also seeking protections on banking and tax issues for the MJ industry. “The STATES Act is not about whether marijuana should be legal or illegal; it is about respecting the authority of states to act, lead and respond to the evolving needs and attitudes of their citizens,” the governors wrote. The letter also expressed support for the SAFE Banking Act , which was approved in March by a House committee. Tha...

Cannabis Watch: Canopy Growth To Book Charge Of Up To $568 Million As Marijuana Restructuring Continues

Canopy Growth Corp. said early Thursday it was halting a range of operations across three continents and expects its restructuring plans to result in a charge of up to C$800 million (567.9 million) in the fiscal fourth quarter. U.S.-traded shares US:CGC CA:WEED of the cannabis company fell 1.9% in afternoon trading. Canopy said it was selling operations in Africa, curtailing cultivation of hemp in the U.S. and Columbia, and shutting down an indoor production facility in Canada. The announcement will result in 85 job cuts, the company said. “When I arrived at Canopy Growth in January, I committed to conducting a strategic review in order to lower our cost structure and reduce our cash burn,” Canopy Chief Executive David Klein said in a statement. Read: As cannabis industry stays largely quiet on coronavirus, this CEO has been sounding the alarm Canopy’s restructuring announcement was expected by investors, Cowen analyst Vivien Azer wrote in a note to clients Thursday. Azer rate...

Norma Pence

Search This Blog